- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
- Cancer Divides. We Unite.
You are here
A multi-institutional team of scientists are making promising discoveries about the tumor microenvironment that could yield breakthroughs in breast cancer early detection and treatment.
The groundbreaking TAILORx Study is the largest trial of its kind with over 10,000 patients enrolled in 6 countries.
BCRF investigators discuss strategies to improve treatment in ER-positive breast cancer at the annual meeting of the American Association for Cancer Research.
BCRF investigator Kornelia Polyak explains how tumors become a mixture of cells and how this relates to metastatic breast cancer.
BCRF investigators Fabrice André, Sarat Chandalapaty, and Nikhil Wagle address the challenges of resistance to CDK4/6 inhibitors.
BCRF Researchers Identify New Drivers of Drug Resistance in Metastatic Estrogen Receptor-Positive Breast Cancer
ESR1 gene fusions drive resistance to endocrine therapies in some tumors and are a new potential target to develop drugs to overcome resistance
BCRF investigators report DNA modifications in breast cancer risk genes may be a result of combined genetic and environmental causes.
BCRF investigators join forces to launch BFOR, an innovative study offering genetic testing for women and men of Ashkenazi Jewish ancestry.
A computer modeling system developed by BCRF investigators allows scientists to simulate tumor cell behavior.
Valentine’s Day is a celebration of love and intimacy, but a breast cancer diagnosis can get in the way.